Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

More PDE5 inhibitors in the Pfizer pipeline

Jan. 18, 1999

Combination of lovastatin and acipimox for type II diabetes and mixed dyslipidemia

Jan. 15, 1999

Amantadine reverses adverse effects of neuroleptic drugs on sexual function in males

Jan. 15, 1999

Amylin files IND for antidiabetes drug and reports on feasibility of alternative delivery routes

Jan. 15, 1999

Amylin gears up for regulatory filing of pramlintide and presents new clinical data

Jan. 15, 1999

Novel compounds developed at Roche for lipid disorders and fungal infections

Jan. 15, 1999

Traditional Chinese medicine shows potential as Rx for hypercholesterolemia

Jan. 14, 1999

TKT and Sumitomo collaborate to commercialize Fabry's disease treatment in Asia

Jan. 14, 1999

Extensive toxicity testing conducted on HMG-CoA reductase inhibitor

Jan. 14, 1999

Mechanism of hypoglycemic activity of YM-268 investigated further

Jan. 14, 1999

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...